Tarsus Pharmaceuticals (TARS) News
NASDAQ: TARSHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
TARS news summary
We found 14 recent headlines mentioning Tarsus Pharmaceuticals (TARS): 0 in the past week and 14 in the past 30 days, most often from Nasdaq, GlobeNewswire, Seeking Alpha. TARS is making an outsized move today, down 6.00% at $73.01, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Tarsus to Participate in Upcoming Investor Conferences", was published by GlobeNewswire on Nov 5, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Tarsus Pharmaceuticals headlines
- Tarsus to Participate in Upcoming Investor ConferencesIRVINE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to attend the following upcoming investor conferences:GlobeNewswire
- HRMY Q3 Earnings Miss Estimates on Higher Costs Despite Wakix GrowthHarmony Biosciences' Q3 earnings missed estimates as higher costs weighed on profits, while Wakix demand and pipeline progress supported its 2026 revenue outlook.NasdaqHRMY, TGTX, TAK, TARS
- Ocugen's Q3 Earnings Match Estimates, Revenues Beat, Stock RisesOCGN's Q3 revenues beat estimates. Shares surge 17.4%. Advancing gene therapy programs target three BLA submissions by 2028.NasdaqOCGN, TGTX, TARS
- Tarsus (TARS) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaq
- Teva Q3 Earnings Beat Estimates, 2026 Revenue View Raised, Stock UpTeva's Q3 earnings beat estimates as strong branded drug sales fueled growth, prompting higher 2026 revenue and product sales guidance.NasdaqTEVA, BMY, TGTX, TARS
- CORT's Q3 Earnings Beat, Higher Product Sales Aid Y/Y RevenuesCorcept's Q3 earnings and revenues beat estimates, driven by strong Lifyorli uptake and higher Korlym sales, as the company advances its pipeline.NasdaqCORT, TGTX, TARS
- Tarsus Pharmaceuticals Q3 Net Loss Widens To $668 Mln On Acquisition Costs As XDEMVY Sales Grow(RTTNews) - Tarsus Pharmaceuticals, Inc. (TARS), a biopharmaceutical company focused on eye care and infectious diseases, reported financial results for the third quarter ended September 30, 2026,…NasdaqTARS, UHAL.B
- Tarsus Pharmaceuticals, Inc. Reports Record XDEMVY Net Product Sales of $194.6 million in Third Quarter 2026Tarsus Pharmaceuticals, Inc. reported its financial results for the third quarter ended September 30, 2026, generating record XDEMVY net product sales of $194.6 million, which represents an increase…Nasdaq
- Tarsus Pharmaceuticals, Inc. GAAP EPS of -$14.40 misses by $10.38, revenue of $194.5M beats by $3.72MSeeking Alpha
- Tarsus Reports Third Quarter 2026 Financial ResultsGenerated record XDEMVY ® net product sales of $194.6 million in the third quarter, an increase of approximately 64% year-over-yearGlobeNewswire
- Gilead Sciences (GILD) Q3 Earnings and Revenues Top EstimatesGilead (GILD) delivered earnings and revenue surprises of +17.51% and +6.21%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?NasdaqGILD, TARS
- Tarsus to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026IRVINE, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Tuesday, November 3,…GlobeNewswire
- Tarsus Names Neera Clase Commercial Chief To Expand XDEMVY Reach And Lead Pipeline Planning(RTTNews) - Wednesday, Tarsus Pharmaceuticals, Inc. (TARS) said it has appointed Neera Clase as Chief Commercial Officer (CCO), effective November 1, 2026.NasdaqABT, ACAD, TARS, BRK.A
- Tarsus Pharmaceuticals Appoints Neera Clase as Chief Commercial OfficerIRVINE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced the appointment of Neera Clase as Chief Commercial Officer (CCO), effective Nov. 1, 2026.…GlobeNewswire